Inovio Pharmaceuticals, Inc. (INO), a clinical-stage biotechnology company, Friday announced the pricing of a public offering of 10 million common shares and also warrants to buy 10 million shares.
The offering is expected to bring in $30 million before subtracting underwriting fees, commissions, and other expenses, and without factoring in any warrant exercises. All of the securities in the offering are being sold by INOVIO.
Each warrant allows the purchase of a share at an exercisable price of $3.76. The combined public offering price for one share and one warrant is $3.00.The offering is expected to close on December 16.
Stephens Inc. is serving as the lead manager, while, Oppenheimer & Co. Inc. and Citizens JMP are serving as the joint book-running managers for the offering.
In the pre-market trade today, INO shares were trading down more than 23% or $0.87 at $2.89 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.